Skip to main content
Premium Trial:

Request an Annual Quote

Temis Acquires i3 Analytics

NEW YORK (GenomeWeb News) – Temis, a semantic solutions provider, has acquired i3 Analytics, a developer of data analytics and visualization technologies for the life sciences, for an undisclosed amount.

According to Temis, the acquisition adds a complementary solution to its existing product portfolio and brings in additional technical know-how to the company that should help expand its life sciences footprint.

I3 Analytics markets Biopharma Navigator, a software-as-a-service platform that provides users with tools to explore and visualize the biopharmaceutical landscape. It gives users access to information that helps them make informed clinical, regulatory, and business decisions.

Temis intends to integrate Biopharma Navigator into Luxid, its flagship platform for identifying and extracting information used to semantically enrich customers' content, and make it available for a variety of applications.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.